Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Survodutide (BI 456906) in Type 2 Diabetes
NCT04153929Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2020
- Primary completion
- Oct 2021
- Modality
- Peptides
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of survodutide in type 2 diabetes mellitus (T2DM) (8 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Absolute Change in HbA1c From Baseline at 16 weeks. Started Apr 2020; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04153929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04153929.